Venetoclax, marketed under the brand name Venclyxto in Europe and Venclexta in the United States, is a targeted therapy medication used in the treatment of certain types of chronic lymphocytic leukemia (CLL) and some forms of small lymphocytic lymphoma (SLL), among other blood cancers. It works by selectively inhibiting the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cells' survival. By blocking this protein, venetoclax helps to trigger the death of cancer cells and slow the progression of the disease. It is often used in combination with other cancer treatments, depending on the specific characteristics of the patient's disease and their overall health. Venetoclax has been hailed as a significant advancement in the treatment of CLL, offering hope to patients with this challenging condition.